- Home
- TBLD vs ANAB Comparison
TBLD vs ANAB Comparison
Compare TBLD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- ANAB
- Stock Information
- Founded
- TBLD 2021
- ANAB 2005
- Country
- TBLD United States
- ANAB United States
- Employees
- TBLD N/A
- ANAB N/A
- Industry
- TBLD Investment Managers
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- ANAB Health Care
- Exchange
- TBLD Nasdaq
- ANAB Nasdaq
- Market Cap
- TBLD 633.0M
- ANAB 621.1M
- IPO Year
- TBLD N/A
- ANAB 2017
- Fundamental
- Price
- TBLD $19.91
- ANAB $20.14
- Analyst Decision
- TBLD
- ANAB Buy
- Analyst Count
- TBLD 0
- ANAB 10
- Target Price
- TBLD N/A
- ANAB $48.00
- AVG Volume (30 Days)
- TBLD 97.5K
- ANAB 500.2K
- Earning Date
- TBLD 01-01-0001
- ANAB 08-06-2025
- Dividend Yield
- TBLD 6.25%
- ANAB N/A
- EPS Growth
- TBLD N/A
- ANAB N/A
- EPS
- TBLD N/A
- ANAB N/A
- Revenue
- TBLD N/A
- ANAB $123,164,000.00
- Revenue This Year
- TBLD N/A
- ANAB N/A
- Revenue Next Year
- TBLD N/A
- ANAB $24.39
- P/E Ratio
- TBLD N/A
- ANAB N/A
- Revenue Growth
- TBLD N/A
- ANAB 304.17
- 52 Week Low
- TBLD $15.80
- ANAB $12.21
- 52 Week High
- TBLD $20.55
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- TBLD 56.02
- ANAB 31.39
- Support Level
- TBLD $19.63
- ANAB $19.55
- Resistance Level
- TBLD $20.39
- ANAB $22.03
- Average True Range (ATR)
- TBLD 0.37
- ANAB 1.50
- MACD
- TBLD 0.01
- ANAB -0.53
- Stochastic Oscillator
- TBLD 64.11
- ANAB 12.05
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).